Moffitt Cancer Center Launches Immunotherapy Contract Research Organization
The new organization will provide end-to-end services for pharmaceutical and biotech companies seeking to accelerate immuno-oncology and cell therapy research.
NEWS PROVIDED BY
Moffitt Cancer Center
Oct 03, 2019, 10:01 ET
TAMPA, Fla., Oct. 3, 2019 /PRNewswire/ — Moffitt Cancer Center announced today the launch of a first-of-its-kind contract research organization (CRO) focused on accelerating immunotherapy research. The subsidiary will provide a one-stop-shop for pharmaceutical and biotech companies to accelerate their immuno-oncology and cell therapy research through collaborative clinical trial support and administration.